ORKA · Oruka Therapeutics, Inc.

Track ORKA — free

$80.54 +3.26 (+4.21%)

Russell 2000 member Rebalance outlook locked

Market Cap

$5.12B

66.21M

Volume · Oct 9 209.65K Avg daily vol (3M) 891.49K

Up next

Latest filing: 10-Q

filed Aug 10, 2026

Q1 2026 earnings call transcript

call held Apr 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+286.5%

Trailing year

Short interest

11.5%

Latest settlement · 11.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +19%

above

Price vs 50-day avg −19%

below

RSI (14) 29

oversold

MACD trend Negative

52-week position 60%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −16%

trailing

6-month return +12%

trailing

YTD return +155%

this year

Relative strength +3%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $95 › 200d $65 — 50d above 200d

Institutional flow Distributing

5 of 257 funds reported for Sep 30 · net -2.6K sh shares

Insider flow Distributing

Net -$420.8K over 90 days · 100% sells

Short interest Falling

11.51% of float · ▼ -2.2% MoM · 11.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

257 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Strong

EPS growth +46%

Y/Y

Free cash flow $-88.4M

Balance sheet $37.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 69%

annualized · 1-yr

Max drawdown −32%

past year

ATR 5.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+19% Bullish

Price vs 50-day avg

−19% Bearish

RSI (14)

29 Neutral

MACD trend

Negative Bearish

52-week position

60% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $95 › 200d $65 — 50d above 200d

Institutional flow Distributing

5 of 257 funds reported for Sep 30 · net -2.6K sh shares

Insider flow Distributing

Net -$420.8K over 90 days · 100% sells

Short interest Falling

11.51% of float · ▼ -2.2% MoM · 11.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

257 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $23 Now $77 · 60% Range high $113

vs 200-day avg +19% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and marketable securities	$1.1B	second quarter of 2026	—
EVERLAST-B enrollment	187	second quarter of 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ORKA Oruka Therapeutics, Inc. this stock	$5.12B	+155.0%	—	—	11.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$127.55B	+11.0%	+46.2%	29.3	1.9%
MRNA Moderna, Inc.	$78.65B	+568.0%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.14B	-4.2%	+20.8%	18.3	2.5%
CSLLY Csl Ltd	$60.24B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

256

% held: 112.5%
Reported: 5 of 257
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

285

View

Short & Settlement

Short Interest Falling

Shares short

7.6M

Days to cover: 11.6d
Change: -170.4K sh

View

Short Volume

Short vol %

39%

As of: Oct 8, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $4.3K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

43.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$420.8K

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-105.4M
EPS diluted: $-4.44

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 24, 2026
This year: 11

View

Proposed Sales

Value

$2.1M

Shares: 25.0K
Filed: Oct 1, 2026

View

Earnings & Events

Webcasts

Last webcast

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ORKA	-7.4%	-15.7%	+12.1%	-7.2%	+155.0%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	-8.7%	-17.8%	+3.2%	-8.7%	+141.5%

Key facts CIK 907654 CUSIP 687604108 13F (30d) 7 filings 7 filers Visit website Investor relations

ORKA · Oruka Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance